Quick Take

The FDA has issued a formal Warning Letter to Velocity Pharma LLC following an inspection that revealed significant Current Good Manufacturing Practice (CGMP) violations. These failures in manufacturing standards have led the agency to classify the company's finished pharmaceutical products as adulterated, indicating they do not meet federal safety and quality requirements.

Why It Matters

Manufacturing lapses in the pharmaceutical industry, particularly those involving products that may require sterility like ophthalmic solutions, represent a significant risk to patient safety. For eye care providers, this regulatory action highlights the importance of monitoring the manufacturing integrity of the products they prescribe or stock. Adulterated products can lead to unpredictable clinical outcomes, including infection or reduced efficacy, making it essential for clinicians to stay informed about FDA enforcement actions against generic and over-the-counter manufacturers.

Key Details

• The FDA issued Warning Letter 676434 to Velocity Pharma LLC on July 17, 2024.
• The warning cites specific violations of Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals.
• Under the Federal Food, Drug, and Cosmetic Act, the company's products are legally classified as adulterated due to these manufacturing failures.
• The violations suggest that the company's processes for manufacturing, processing, or holding drugs do not ensure their quality, safety, and purity.

Practice Implications

Clinicians and practice owners should review their current inventory for any pharmaceutical products manufactured by Velocity Pharma LLC. Given the FDA's classification of these products as adulterated, providers should consider suspending their use and advising patients to check their over-the-counter medications for this manufacturer until compliance issues are resolved.

Who's Affected

What's Next

Velocity Pharma LLC must respond to the FDA with a comprehensive plan to correct the identified CGMP violations. Failure to address these concerns could lead to further regulatory action, including product seizures, injunctions, or a total halt in distribution.